MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.

Caenepeel, Sean

MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. [electronic resource] - Oncotarget Mar 2017 - 17795-17809 p. digital

Publication Type: Journal Article

1949-2553

10.18632/oncotarget.14855 doi


Adaptor Proteins, Signal Transducing--metabolism
Animals
Antineoplastic Agents--pharmacology
Apoptosis--drug effects
Benzamides--pharmacology
Cell Line, Tumor
Dipeptides--pharmacology
Diphenylamine--analogs & derivatives
Drug Resistance, Neoplasm
Female
Hepatocyte Growth Factor--pharmacology
Humans
Indoles--pharmacology
MAP Kinase Signaling System--drug effects
Melanoma--genetics
Mice
Mice, Nude
Protein Kinase Inhibitors--pharmacology
Proto-Oncogene Proteins B-raf--antagonists & inhibitors
Proto-Oncogene Proteins c-met--antagonists & inhibitors
Pyridones--pharmacology
Sulfonamides--pharmacology
Triazoles--pharmacology
Vemurafenib
Xenograft Model Antitumor Assays